Oncolytics and others advance cancer therapies as the FDA approves 16 new oncology treatments in 2024
Debate grows as Minister Holland's comments on Bill C-64 raise questions in Senate discussions
Maximus Rose assists in cutting unsustainable benefit costs
Lilly Canada finalizes a major deal with pCPA, advancing access to a new UC treatment across Canada
Small teams specialist outlines what smaller Canadian employers are doing to manage, and the lessons they hold for larger organizations
Identifying areas where drug costs are rising, and the unique challenges posed by GLP-1 drugs
